advanced glycation

Advanced glycation end products are the outcome of non-enzymatic glycation reactions involving biomolecules such as proteins, lipids, nucleic acids, and reducing sugars. Advanced glycation end products are frequently employed in investigating pathological mechanisms associated with diabetes, ageing, and chronic diseases.

Cassiaside C (Toralactone 9-O-β-D-gentiobioside), a naphthopyrone extracted from Cassia tora seeds, demonstrates in vitro inhibitory activity against the formation of advanced glycation end products (AGE).

Ipriflavone (Osteofix) (Osteofix) is a feed additive and a catabolic agent. It is used to inhibit bone resorption.

Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD).

FPS-ZM1 is a high-affinity, RAGE-specific inhibitor that obstructs Aβ binding to the V domain of RAGE.

4'-Methoxyresveratrol (4'-O-Methylresveratrol) is a natural product from the roots of *Rheum palmatum* L., with significant hypoglycemic, anti-inflammatory, and antioxidant effects. 4'-Methoxyresveratrol alleviates AGE-induced inflammation by suppressing RAGE-mediated MAPK/NF-κB signaling pathway and NLRP3 inflammasome activation.

D-Psicose (D-Allulose) is an orally active rare sugar. It effectively inhibits p38-MAPK phosphorylation and MCP-1 expression, while blocking the AGEs/RAGE/NF-kappaB signaling pathway. D-Psicose demonstrates significant bioactivity in research involving pancreatic beta-islet protection, hyperglycemia improvement, lipid metabolism regulation, and the mitigation of high-fat diet-induced non-alcoholic fatty liver disease (NAFLD).

ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).

Bromelain is an anti-inflammatory drug derived from pineapple stem. It acts through down-regulation of plasma kininogen, degradation of advanced glycation end-product receptors, inhibition of Prostaglandin E2 expression, and regulation of angiogenic bioma

Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor that has proven effective in reducing systolic blood pressure and providing therapeutic benefits for patients with diastolic.

LR-90, an advanced glycation end product (AGE) inhibitor, is utilized in diabetic animal model research. This compound effectively suppresses inflammatory responses in human monocytes.

Pyridoxylamine (pyridoxamine) is an inhibitor of advanced glycation end production (AGEs) and lipoxidation end products (ALEs).

Fructosyl-lysine is the precursor to glucosepane. Fructosyl-lysine is a lysine–arginine protein cross-link that can be an indicator in diabetes detection. Fructosyl-lysine is an amadori glycation product from the reaction of glucose and lysine by the Maillard reaction.

Esmolol is an ultra-short-acting, cardioselective β1-adrenergic receptor blocker. Esmolol exerts antiarrhythmic effects by regulating the NK1 receptor (neurokinin 1 receptor) signaling pathway and effectively improves myocardial dysfunction after cardiopulmonary resuscitation.Esmolol can positively promote diabetic wound healing by inhibiting aldose reductase activity, reducing advanced glycation end-product formation, and promoting fibroblast migration.Esmolol serves as an important tool drug for mechanistic studies on cardiovascular diseases such as arrhythmias and diabetic foot ulcers.

RuDiOBn exhibits low antioxidant activity by scavenging DPPH and ABTS free radicals with scavenging rates of 13.2% and 5.9% at a concentration of 100 μg/mL. It inhibits collagen glycation and reduces the formation of advanced glycation end-products (AGE) with an IC50 of 2.45 μg/mL. RuDiOBn also enhances fibroblast proliferation and migration, stimulates collagen synthesis, and aids in skin repair and regeneration while inhibiting collagenase.

Gemigliptin (LC15-0444) tartrate hydrate is a selective, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 value of 10.3 nM for human recombinant DPP-4. It exhibits strong anti-glycation properties and is used in research on advanced glycation end product-related diabetic complications.

(R)-DRF053 is a CDK inhibitor that suppresses Cdk5 and facilitates the formation of ductal progenitor β cells. Additionally, (R)-DRF053 inhibits the uptake of Dil-ox-LDL and the expression of the CD36 gene in U937 cells induced by advanced glycation end-products (AGEs).

MG-H1 is a ligand for the receptor for advanced glycation end-products (RAGE), with a Kd value of 4.12 nM. It is capable of binding to human umbilical vein endothelial cells. MG-H1 is applicable in diabetes research.

Azeliragon is a potent and orally active inhibitor of RAGE (receptor for advanced glycation endproducts), a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain.

Alagebrium is a advanced glycation endproducts (AGE) cross-link breaker.

Homocarnosine is a brain-specific dipeptide composed of γ-aminobutyric acid (GABA) and histidine. As an inhibitory neurotransmitter, homocarnosine is synthesized from GABA within neurons and exerts anticonvulsant effects by enhancing GABA receptor signaling pathways. Homocarnosine also possesses antioxidant and anti-inflammatory properties; it scavenges peroxyl radicals, chelates transition metal ions such as copper, prevents oxidative damage to DNA, and inhibits the formation of advanced glycation end products (AGEs).

Homocarnosine acetate is a dipeptide unique to brain consisting of γ-aminobutyric acid (GABA) and histidine. Homocarnosine acetate has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation

Pimagedine is a prototype therapeutic agent for the prevention of formation of advanced glycation endproducts. Pimagedine reacts rapidly with α,β-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone to prevent the formation of advanced glycation endproducts (AGEs).

Advanced glycation end products (AGEs) are compounds formed by non-enzymatic chemical reactions following the bonding of sugars to proteins or lipids during diabetes, uremia, aging, rheumatic arthritis, and other conditions. A receptor for the AGEs (RAGE) binds certain members of this class to initiate cell signaling.[1][2] Pentosidine is a well-characterized natural AGE that is often used as a biomarker for the production of all AGEs. While pentosidine can be measured in urine, the majority of this AGE is catabolized before excretion.[3] Reference:[1]. Neeper, M., Schmidt, A.M., Brett, J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. The Journal of Biological Chemisty 267(21), 14998-15004 (1992).[2]. Brett, J., Schmidt, A.M., Yan, S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. American Journal of Pathology 143(6), 1699-1712 (1993).[3]. Miyata, T., Ueda, Y., Horie, K., et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney International 53, 416-422 (1998).